img

Post-pandemic Era Global Essential Thrombocythemia Drug Market Segment Research Report 2024

Published on: 2024-01-04 | No of Pages : 212 | Industry : Medical Devices & Consumables Research Center

Publisher : XMR | Format : PDF

Post-pandemic Era Global Essential Thrombocythemia Drug Market Segment Research Report 2024

Summary

The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.

The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.

Regional Economic ProspectsGrowth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.

The global Essential Thrombocythemia Drug market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to MR Accuracy Reports analysis, The segment in Essential Thrombocythemia Drug market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China Essential Thrombocythemia Drug production is XX (K Units). US market value in 2021 is about USD XX billion, and US Essential Thrombocythemia Drug production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe Essential Thrombocythemia Drug production is XX (K Units).

Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Essential Thrombocythemia Drug Market by MR Accuracy Reports Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Essential Thrombocythemia Drug Market?
AbbVie Inc
Aop Orphan Pharmaceuticals AG
F. Hoffmann-La Roche Ltd
Galena Biopharma Inc
Incyte Corp
Italfarmaco SpA
MEI Pharma Inc
PharmaEssentia Corp
Major Type of Essential Thrombocythemia Drug Covered in MR Accuracy Reports report
Givinostat
Idasanutlin
Pracinostat
Ruxolitinib Phosphate
Others
Application Segments Covered in MR Accuracy Reports Market
Research Center
Hospital
Clinic
Others

For any other requirements, please feel free to contact us and we will provide you customized report.

Table of Content

Table of Contents

Global Essential Thrombocythemia Drug Market Segment Research Report 2021
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Essential Thrombocythemia Drug Market by Value
2.2.1 Global Essential Thrombocythemia Drug Revenue by Type
2.2.2 Global Essential Thrombocythemia Drug Market by Value (%)
2.3 Global Essential Thrombocythemia Drug Market by Production
2.3.1 Global Essential Thrombocythemia Drug Production by Type
2.3.2 Global Essential Thrombocythemia Drug Market by Production (%)

3. The Major Driver of Essential Thrombocythemia Drug Industry
3.1 Historical & Forecast Global Essential Thrombocythemia Drug Demand
3.2 Largest Application for Essential Thrombocythemia Drug (2017-2027)
3.3 The Major Downstream Company in China Market 2021

4. Global and Regional Essential Thrombocythemia Drug Market
4.1 Regional Market Size in Terms of Production & Demand (2021)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Essential Thrombocythemia Drug Market
4.4 Mergers & Acquisitions, Expansion Plans

5. US Essential Thrombocythemia Drug Production, Demand (2017-2027)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

6. Europe Essential Thrombocythemia Drug Production, Demand (2017-2027)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

7. China Essential Thrombocythemia Drug Production, Demand (2017-2027)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

8. Japan Essential Thrombocythemia Drug Production, Demand (2017-2027)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

9. India Essential Thrombocythemia Drug Production, Demand (2017-2027)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

10. Korea Essential Thrombocythemia Drug Production, Demand (2017-2027)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

11. Southeast Asia Essential Thrombocythemia Drug Production, Demand (2017-2027)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)

12. Global Essential Thrombocythemia Drug Average Price Trend
12.1 Market Price for Each Type of Essential Thrombocythemia Drug in US (2017-2021)
12.2 Market Price for Each Type of Essential Thrombocythemia Drug in Europe (2017-2021)
12.3 Market Price for Each Type of Essential Thrombocythemia Drug in China (2017-2021)
12.4 Market Price for Each Type of Essential Thrombocythemia Drug in Japan (2017-2021)
12.5 Market Price for Each Type of Essential Thrombocythemia Drug in India (2017-2021)
12.6 Market Price for Each Type of Essential Thrombocythemia Drug in Korea (2017-2021)
12.7 Market Price for Each Type of Essential Thrombocythemia Drug in Southeast Asia (2017-2021)

13. Industrial Chain (Impact of COVID-19)
13.1 Essential Thrombocythemia Drug Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Essential Thrombocythemia Drug

14. Essential Thrombocythemia Drug Competitive Landscape
14.1 AbbVie Inc
14.1.1 AbbVie Inc Company Profiles
14.1.2 AbbVie Inc Product Introduction
14.1.3 AbbVie Inc Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.1.4 Strategic initiatives
14.2 Aop Orphan Pharmaceuticals AG
14.2.1 Aop Orphan Pharmaceuticals AG Company Profiles
14.2.2 Aop Orphan Pharmaceuticals AG Product Introduction
14.2.3 Aop Orphan Pharmaceuticals AG Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.2.4 Strategic initiatives
14.3 F. Hoffmann-La Roche Ltd
14.3.1 F. Hoffmann-La Roche Ltd Company Profiles
14.3.2 F. Hoffmann-La Roche Ltd Product Introduction
14.3.3 F. Hoffmann-La Roche Ltd Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.3.4 Strategic initiatives
14.4 Galena Biopharma Inc
14.4.1 Galena Biopharma Inc Company Profiles
14.4.2 Galena Biopharma Inc Product Introduction
14.4.3 Galena Biopharma Inc Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.4.4 Strategic initiatives
14.5 Incyte Corp
14.5.1 Incyte Corp Company Profiles
14.5.2 Incyte Corp Product Introduction
14.5.3 Incyte Corp Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.5.4 Strategic initiatives
14.6 Italfarmaco SpA
14.6.1 Italfarmaco SpA Company Profiles
14.6.2 Italfarmaco SpA Product Introduction
14.6.3 Italfarmaco SpA Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.6.4 Strategic initiatives
14.7 MEI Pharma Inc
14.7.1 MEI Pharma Inc Company Profiles
14.7.2 MEI Pharma Inc Product Introduction
14.7.3 MEI Pharma Inc Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.7.4 Strategic initiatives
14.8 PharmaEssentia Corp
14.8.1 PharmaEssentia Corp Company Profiles
14.8.2 PharmaEssentia Corp Product Introduction
14.8.3 PharmaEssentia Corp Essential Thrombocythemia Drug Sales, Revenue (2017-2021)
14.8.4 Strategic initiatives
15. Conclusion


List of Figure

List of Tables and Figures

Figure 1. Total Demand by Application of Essential Thrombocythemia Drug Industry (Volume)
Figure 2. Essential Thrombocythemia Drug Production & Demand by Regions in 2021
Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
Figure 4. The Top 10 and 5 Players Market Share by Essential Thrombocythemia Drug Revenue in 2021
Figure 5. US Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Essential Thrombocythemia Drug Production, Demand (2017-2027)
Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Essential Thrombocythemia Drug Revenue, by Type (Million USD) (2017-2027)
Table 4. Essential Thrombocythemia Drug Production, by Type (K Unit) (2017-2027)
Table 5. Essential Thrombocythemia Drug Demand (K Unit) by Application (2017-2027)
Table 6. Essential Thrombocythemia Drug Demand (Million USD) by Application (2017-2027)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2021)
Table 9. Regional Market Share in Terms of Revenue (2021&2027)
Table 10. Ranking of Global Top Essential Thrombocythemia Drug Companies by Revenue, Concentration Ratio in 2021
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Essential Thrombocythemia Drug Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in US (2017-2021)
Table 53. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in Europe (2017-2021)
Table 54. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in China (2017-2021)
Table 55. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in Japan (2017-2021)
Table 56. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in India (2017-2021)
Table 57. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in Korea (2017-2021)
Table 58. Market Price (USD/Unit) for Each Type of Essential Thrombocythemia Drug in Southeast Asia (2017-2021)
Table 59. Key Downstream Customer in Each Application Field
Table 60. AbbVie Inc Profiles
Table 61. AbbVie Inc Essential Thrombocythemia Drug Product Introduction
Table 62. AbbVie Inc Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 63. AbbVie Inc Strategic initiatives
Table 64. Aop Orphan Pharmaceuticals AG Profiles
Table 65. Aop Orphan Pharmaceuticals AG Essential Thrombocythemia Drug Product Introduction
Table 66. Aop Orphan Pharmaceuticals AG Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 67. Aop Orphan Pharmaceuticals AG Strategic initiatives
Table 68. F. Hoffmann-La Roche Ltd Profiles
Table 69. F. Hoffmann-La Roche Ltd Essential Thrombocythemia Drug Product Introduction
Table 70. F. Hoffmann-La Roche Ltd Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 71. F. Hoffmann-La Roche Ltd Strategic initiatives
Table 72. Galena Biopharma Inc Profiles
Table 73. Galena Biopharma Inc Essential Thrombocythemia Drug Product Introduction
Table 74. Galena Biopharma Inc Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 75. Galena Biopharma Inc Strategic initiatives
Table 76. Incyte Corp Profiles
Table 77. Incyte Corp Essential Thrombocythemia Drug Product Introduction
Table 78. Incyte Corp Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 79. Incyte Corp Strategic initiatives
Table 80. Italfarmaco SpA Profiles
Table 81. Italfarmaco SpA Essential Thrombocythemia Drug Product Introduction
Table 82. Italfarmaco SpA Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 83. Italfarmaco SpA Strategic initiatives
Table 84. MEI Pharma Inc Profiles
Table 85. MEI Pharma Inc Essential Thrombocythemia Drug Product Introduction
Table 86. MEI Pharma Inc Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)
Table 87. MEI Pharma Inc Strategic initiatives
Table 88. PharmaEssentia Corp Profiles
Table 89. PharmaEssentia Corp Essential Thrombocythemia Drug Product Introduction
Table 90. PharmaEssentia Corp Essential Thrombocythemia Drug Sales (Unit), Revenue (Million USD) (2017-2021)

Select User License

$2700 Single Licence
$4500 Enterprise Licence
$5900 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries